^
    Back
    Association details:
    Biomarker:VHL mutation
    Cancer:Cholangiocarcinoma
    Drug:sunitinib (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Cancer Biol Ther
    Title:

    Third-line sunitinib treatment in a VHL-mutated metastatic intrahepatic cholangiocarcinoma: a case report and literature review

    Excerpt:
    We herein present a case of a 46-y-old Asian iCCA patient with multiple metastases in lung, bone, and liver...According to next- generation sequencing result of somatic Von Hippel-Lindau (VHL) gene mutation, the patient was administered third-line sunitinib and obtained a relatively longer survival of 9 months after taking sunitinib.
    DOI:
    https://doi.org/10.1080/15384047.2020.1769418